Hu5F9-IgG2σ

Hu5F9-IgG2σ is an Fc-engineered, humanized monoclonal antibody directed against CD47, a cell surface protein that functions as a "don't-eat-me" signal to inhibit phagocytosis by macrophages. It is a variant of magrolimab (Hu5F9-G4) featuring an IgG2σ (sigma) constant region, which is designed to be immunologically "silent" by minimizing binding to Fcγ receptors and complement proteins. This modification aims to reduce the hemagglutination and anemia often associated with CD47-targeting antibodies that possess active Fc regions. By blocking the interaction between CD47 on tumor cells and Signal Regulatory Protein Alpha (SIRPα) on myeloid cells, Hu5F9-IgG2σ promotes the pro-phagocytic clearance of cancer cells. Preclinical research has demonstrated its efficacy in T-cell acute lymphoblastic leukemia (T-ALL), especially when combined with other immunotherapies like daratumumab.

Other names

Fc-modified Hu5F9-G4